LG Chem: Carcinoma, Renal Cell trials

The registry lists 10 Carcinoma, Renal Cell studies with LG Chem as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 3Phase 2 4Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLCRecruitingNCT06332755Phase 1
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedNCT02627963Phase 3Results posted
• A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCTerminatedNCT01673386Phase 2Results posted
• A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01297244Phase 2Results posted
• An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).CompletedNCT01076010Phase 3Results posted
• A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01030783Phase 3Results posted
• A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaCompletedNCT00502307Phase 2Results posted
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedNCT04987203Phase 3
• Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2
• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00563147Phase 1